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Systemic Lupus Erythematosus (SLE) is one of the most common systemic 
autoimmune diseases (1;2). SLE is characterized by a highly variable clinical presentation that 
may range from mild skin involvement to life-threatening multiorgan failure. Currently, no 
cure exists for the disease, but with appropriate management, SLE is no longer a rapidly fatal 
disease as it was some decades ago. SLE has become a chronic disease with an unpredictable 
disease course, generally characterized by alternating periods of quiescence and exacerbations 
of disease activity. 
The basis for virtually all disease manifestations is the occurrence of sterile 
inflammation that may affect any of the body’s organs system and can ultimately lead to 
tissue scarring and subsequent failure of organ function. The underlying pathological 
processes in SLE are extremely complex due to the varying severity and longevity of 
inflammation, and diverse composition of the inflammatory infiltrates. This has led many 
investigators to believe that SLE represents a common name for a syndrome that comprises 
various distinct conditions (3). The early beginning of this process is most probably a misled 
activation of immune cells, resulting in an immune response against self antigens which 
includes the production of antibodies against self antigens (autoantibodies). This 
immunological self-intolerance is regarded as an early hallmark of SLE and it has become 
clear that this is due to a complex process involving a variety of  molecules and cells (4). 
While more than a hundred different types of autoantibodies have now been reported in the 
serum of SLE patients (5), the evidence for a pathogenic role for many of these autoantibodies 
is still weak. 
Renal involvement affects about 25 – 60 % of patients with SLE, and is one of the 
more serious manifestations as it can lead to complete renal insufficiency (6-10). Despite 
decades of research efforts, the pathogenesis of lupus nephritis (LN) is still not fully 
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understood. However, LN is the most widely studied example of immune complex mediated 
inflammation. It has become clear that there is an association between the development of LN 
and the presence of a particular subgroup of autoantibodies against native DNA in serum and 
renal tissue. These anti-dsDNA antibodies also have a role in the current diagnosis and 
management of SLE and LN (4). 
While some of the pathways in SLE progression have been elucidated, the cause(s) of 
SLE remain elusive. Technical opportunities for genetic research have increased rapidly in 
recent years, and studies of how changes in DNA- and RNA affect the structure and function 
of immunological molecules have become a topic of intense research in various diseases. 
With regard to SLE, a new hypothesis sustain, that the different clinical phenotypes may be a 
mirror of genetic variation in one or more of the molecules that are involved in 
immunological reactions (11). Given the complexities of both immunopathology and the 
genetic basis of SLE, many questions are yet unsolved and a lot of work is in progress. The 
ultimate hope is however, that in the future, knowledge of a genetic signature in each 
individual SLE patient could help to predict and possibly prevent disease and complications. 
 
Background 
History of Systemic Lupus Erythematosus 
The word lupus is a Latin term which means wolf. "Lupus" has been used since the 
Middle Ages by the Romans to describe ulcerative lesions in the skin similar to the results of 
a wolf bite. The first scientific publication that mention these skin lesions emerged in the 
1800s, first by Pierre Cazenave in 1838 (12) and 7 years later the butterfly rash that is typical 
of SLE was described by Ferdinand von Hebra (13). Some years after that Cazenave 
introduced the term lupus érythèmateux (14) to distinguish the characteristic skin lesions from 
the more common lupus vulgaris which was the result of tuberculosis. In 1872, Moriz Kaposi 
recognised the potential dangerous systemic nature of the disease (15) and at turn the of the 
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century, William Osler described patients with disseminated lupus (16). Histopathological 
descriptions of disseminated lupus began with the work of Liebman and Sachs in 1924 on 
verrucucous endocarditis (17) and eleven years later Baehr et al described the characteristic 
wire loop lesions in the glomeruli (18).  
Lupus erythematosus (LE) was recognized as a connective tissue disease of 
autoimmune nature in 1948 with Hargraves’ description of the LE cell, which eventually 
became the first diagnostic tool for SLE (19). LE cells were subsequently linked to the 
gamma globulin fraction in the plasma of SLE patients. The discovery of LE cells in 
combination with a new immunofluorescence technique to confirm antigen localization in 
tissues, led to the development of antinuclear antibody (ANA) assay. The test's sensitivity for 
SLE was described by George Friou in 1958 (20) and opened up for a series of investigations 
of the gamma globulin fraction and the subsequent description of various autoantibodies, 
including anti-dsDNA. Over time, this has led to the development of more specific diagnostic 
and prognostic autoantibody assays, which are easier to use than the LE cell test. The 
implementation of new assays to monitor the disease has led most laboratories discard the LE 
cell test. These achievements coincided with the discovery of the strong anti-inflammatory 
properties of corticosteroid drugs and their subsequent introduction in clinical practice. This 
breakthrough led to the Nobel Prize for rheumatologist Philip Hench in 1950 and was soon 
also found to be an excellent short term therapy for patients with SLE and especially for LN 
when used in higher doses (21). Soon thereafter it was observed that the long term 
administration of steroid was associated with clinical drawbacks, and this has paved the way 
for the introduction of other immunomodulating/cytotoxic drugs in the treatment of SLE 
patients. Of note, none of the currently recommended nonspecific immunosuppressive drugs 
used in SLE treatment have been formally approved by regulatory agencies such as the U.S. 
Food and Drug Administration. In the present era of targeted biological therapies, is the hope 
 11
that specific intervention by monoclonal antibodies against cytokines, cell receptors or 
inhibition of intracellular signalling pathways, will eventually allow tailored therapy in SLE. 
 
 
Systemic Lupus Erythematosus (SLE)  
Classification 
As SLE causes a wide spectrum of clinical symptoms and serological patterns, 
clinicians must deal with a diagnostic challenge, as they need to distinguish SLE 
manifestations from infections or other common diseases. In order to facilitate the formal 
scientific communication about the disease, a subcommittee created by the American 
Rheumatism Association (ARA), published preliminary criteria for classification of SLE in 
1971 (22).The subcommittee revised these criteria in 1982 (ACR82) -  after ARA changed its 
name to the American College of Rheumatology (ACR). The 1982 revision was based on a 
comparison of findings in a large cohort of SLE patients followed in 18 different US hospitals 
for a mean period of seven years and a control cohort that included patients with rheumatoid 
arthritis, osteoarthritis and scleroderma. The final ACR82 criteria (23) were derived from 
cluster analyses and had high sensitivity and specificity (96 % for both) (Table 1) which was a 
considerable improvement compared to the 1971 criteria. In ACR82, only eleven items were 
included, among these a positive test for antinuclear antibodies (ANA) as a separate item and 
antibodies (Ab) to double-stranded DNA (dsDNA) or to Smith antigen (Ag) as a part of  the 
immunological item. These immunological tests replaced clinical manifestations such as 
Raynaud’s phenomenon and alopecia. The ACR82 criteria were again modified in 1997 (24), 
when the finding of LE cells was replaced with the presence of antiphospholipid Ab (aPL) 
encompassing anti-cardiolipin Ab (aCL) or lupus anticoagulant (LA). This update was 
consensus-based and reflected the fact that most laboratories did no longer perform the LE 
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cell assay. The updated classification criteria for SLE from 1997 (ACR97) have not yet been 
formally evaluated, but these criteria aim to be optimally sensitive and specific.  
The 82ACR and 97ACR criteria sets require involvement of different organ systems 
according to strict definitions where at least four of eleven classification criteria have to be 
fulfilled. The purpose of developing SLE classification criteria was to ensure homogeneity in 
clinical trials and population studies, but the main drawback of these criteria sets was the 
exclusion of a considerable number of other relevant disease manifestations. During the first 
years of the disease, patients often have clinically relevant symptoms excluded from ACR97, 
e.g. alopecia or Raynaud’s phenomenon. This means that patients with a clinical diagnosis of 
SLE need not always meet the requirements of the ACR97, as the criteria are not well suited 
for the early stages of the disease. These considerations partly underlie an ongoing 
international effort to update the SLE classification criteria once more (25). 
 
Epidemiology  
SLE has been recognized worldwide and occurs in all ethnic groups, although regional 
variations in frequency and severity have been reported. The lowest incidence rates are 
observed in Caucasian populations (26). Studies from Scandinavia show that the average 
annual incidence rate (AIR) of SLE varies from 1.5 to 4.8 per 100,000 (27-32). Compared to 
countries with mostly Caucasian population, the incidence of SLE in multi-ethnic countries, 
such as United Kingdom and the Caribbean Islands is significantly higher (28;33), similar to 
the disease rate in USA where the reported AIR vary from 1.8 to 7.6 per 100,000 (34-37). 
The prevalence of a disease is naturally dependent on its incidence rate and its disease 
severity in terms of mortality. Epidemiological studies from USA report a wide range in SLE 
prevalence with rates varying from 14.6 to 122 per 100,000 (34-39). These higher rates 
exceed prevalence rates in studies from Scandinavia with a reported range from 22.0 to 68.0 
per 100,000 (30-32;40). During the last decades, standardized mortality ratios (SMR) have 
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declined gradually from 10.1 in the 1970s to 2.4 (41;42). Simultaneously, 5 years survival 
rates have improved from approximately 50 % in the 1950s to over 90 % at present (41;43-
45), resulting in increased prevalence of SLE over the last decades. 
Traditionally, SLE has been considered as a disease among women of childbearing age 
(34;39), but nowadays the highest prevalence at 130 per 100,000 is seen in postmenopausal 
women (Paper I). This change is a consequence of the increased survival of SLE patients in 
combination with increased life expectancy in the general population. The variability in 
prevalence and incidence rates of SLE are explained by the effect of ethnicity or study-design, 
since some studies include only hospitalized SLE patients while others include patients 
diagnosed by general practitioners or self reported SLE disease (26).  
 
Clinical manifestations  
SLE is a pleomorphic disease where many organ systems may be involved either alone 
or in combination. SLE patients can thus presents combinations of various rashes, arthritis, 
pleurisy, proteinuria, Raynaud’s phenomenon, seizures, or fever of unknown origin. 
Nonetheless, some manifestations of SLE are more frequent than others, such as rash or 
arthritis, which is seen in more than two-thirds of patients during the course of the disease. 
Involvement of the nervous system is also frequent and is seen in 14-90 % of SLE patients 
depending on the type of CNS involvement studied (46). A common term for affection of the 
nervous system is "neurolupus" and this involves cognitive, psychiatric, focal and diffuse 
central and peripheral symptoms. In addition, vasculitis is common in SLE and may involve 
small and large vessels, resulting in urticaria and sometimes gangrene of a finger or part of a 
limb. A major complication in SLE is the development of lupus nephritis (LN) and since LN 
is emphasized in this thesis it will be discussed in a separate paragraph. 
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 Almost per definition, the most frequent cumulative laboratory finding in SLE is a 
positive ANA test, even though low complement (C3 and/or C4) and positive tests for various 
antibodies also are common (8;47;48). In addition to these immunologic findings, elevated 
erythrocyte sedimentation rate (ESR), anemia of chronic disease, leucopenia, 
lymphocytopenia and thrombocytopenia are regularly seen in patients with active SLE 
disease.   
 
Assessment of disease activity  
Given the pleiotropic nature of the disease, the assessment of disease activity is not 
easy and several different instruments have been developed to quantify disease activity. These 
include among others BILAG (49)  that rates eight organ systems with scores based on the 
principles of intention to treat and ECLAM (50-52) that comprise 15 weighted clinical and 
serological items but exclude the antibody testing. Another instrument is SLE disease activity 
index (SLEDAI), which was developed at the University of Toronto in Canada and measures 
disease activity within the 10 last days (53). In 2000 it was updated to SLEDAI-2K that 
incorporate the presence of some persisting disease features, using a timeframe of the last 10 
or 30 days (54). SLEDAI was developed through a model of complete assessment of disease 
activity by experienced clinicians. Therefore it represents the consensus of a group of experts 
and has subsequently been validated as a reliable and reproducible measure of disease activity 
that is sensitive to change over time. The choice for SLEDAI (Table 2) as measurement of 
disease activity in our registry was based on its validity, sensitivity to change and earlier 
experiences of its ease of use. 
 SLEDAI includes 24 clinical and laboratory variables that are weighted differently, 
where life threatening events such as cerebral manifestations and vasculitis have the highest 
score (score 8). Disease activity scores may in theory range from 0 to 105, but in practice 
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rarely exceeds the 40 mark. Four different renal manifestations associated with LN are given a 
score of 4 each, that leading to a potential SLEDAI score of 16 in patients with LN, which 
may increase to 20 if also positive anti-dsDNA Ab and low complement are scored with a 
weight of 2 each (55). Another simple index used in these studies is the visual analogue scale 
(VAS) that consists of a line of 10 cm along which the patient or the physician draws a 
perpendicular mark, reflecting their assessment of overall severity of disease activity. The 
patient VAS gives an overall impression of how patients experience the effects of disease and 
includes subjective symptoms like fatigue, myalgia, arthralgia and abdominal pain (55). The 
physician VAS is a reflection of how active the attending doctor considers the disease state to 
be, especially with regard to the need for intervention. In many ways, physician VAS 
resembles the old case note summary describing whether patients are doing well, unchanged 
or poorly.   
  
Assessment of organ damage 
 As a result of the improved survival for SLE patients, there was a need to develop a 
system that measures less crude outcomes of the disease. Since the inflammatory process of 
SLE can result in specific organ damage, the Systemic Lupus International Collaborating 
Centre Clinics (SLICC) Working Group has developed the  SLICC Damage Index (SDI) (56). 
SDI includes assessment of 12 organ systems and record damage regardless of its cause. 
Damage may result from previous disease activity resulting in organ failure, such as renal 
failure or neurocognitive abnormality, or may be the result of side effects of medications. It 
may also result from intercurrent illness, such as vascular ischemia, diabetes, surgery or 
cancer.  
SDI scores are based on accurate definitions of organ damage resulting in maximum 
scores of  6 for neuropsychiatric-, cardiovascular-, gastrointestinal- and musculoskeletal 
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domains, while the maximum score for the renal domain is 3 (renal failure). Since SDI is to be 
distinguished from disease activity in SLE, the relevant feature must be present continuously 
for at least six months. Maximum SDI scores can theoretically reach 47, but this is unlikely to 
be compatible with life (57). 
 
Outcome  
Although SLE is mainly a chronic disease, remissions (disease quiescence lasting for 
at least one year in the absence of any immunosuppressive drug treatment) occur in 2-10 % of 
the patients (58). The life expectancy for SLE patients has increased during the last decades 
thanks to a combination of various factors, including increased availability of medical 
treatment, advances of anti-inflammatory therapy and the development of new cytotoxic 
drugs (37;41). In addition, the introduction and more widespread application of diagnostic 
assays leads to earlier diagnosis of SLE patients and subsequent inclusion of milder cases 
which are also important factors in the improved survival (45). Since cardiovascular disease is 
a frequent cause of death, the awareness and general advances in preventive therapy for 
primary and secondary thrombotic complications may have had some impact on the improved 
life expectancy (59-62). 
Infections remain a cause of increased mortality of SLE, even though the types of 
infections are similar to the general population (63). In periods of high disease activity, 
intensive immunosuppressive treatment that often includes high dose corticosteroids and 
cyclophosphamide is frequently required. Such treatment results in a desired impairment of 
the immune response, but leaves the patient vulnerable to microorganisms that may cause 
ordinary as well as opportunistic infections (64). In addition, genetic factors like specific 
variants in the genes encoding mannose-binding lectin and Fcγ receptors may predispose 
certain SLE patients to develop infections. Thus, an intrinsic risk for infectious complications 
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that is independent of therapy but related to impaired immune defence exists in these patients 
(65). Therefore in situations with intensive treatment, clinicians together with patients need to 
continuously balance the intensity of treatment with the risk of serious and potentially fatal 
infections. 
 
Lupus nephritis (LN) 
Epidemiology of LN 
 Depending on the ethnicity in the population, about 25 % to 60 % of adults with SLE 
disease develop LN (defined as renal inflammation caused by SLE) and this happens mainly 
during the first years of the disease course (6-8). The prevalence of LN is lowest in Caucasian 
population and highest in Hispanics, Asian, Afro-Caribbean and African-Americans (9;66). 
Currently, there are indications that kidney involvement is becoming less frequent in SLE 
(31).  
Aggressive immunosuppressive therapy has improved the prognosis of SLE patients 
with renal disease considerably, however 5-20 % still progress to end-stage renal disease 
(ESRD) within 10 years following the diagnosis of nephritis (6;67). In addition to an 
increased morbidity, patients with renal damage have also a decreased 5-years survival 
compared to the rest of SLE patients (70-80 % vs. 90 %) (68;69). 
 
Diagnosis of LN 
  LN has a highly variable presentation which can range from no clinical symptoms 
such as proteinuria, microscopic haematuria, new onset or worsening hypertension to severe 
nephritic syndrome or acute renal failure. Since LN is often asymptomatic, regular control of 
serum creatinine, urine dipstick, and if abnormal, microscopy of urine has to be performed.  
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LN  occurs according to SLEDAI definition (53) if any of the four following criteria 
are met; 1. Urinary casts (Heme-granular or red blood cells casts.) 2. Haematuria (> 5 red 
blood cells/high power field, excluding stone, infection and other causes). 3.  Proteinuria 
(>0.5 g/24h, regarding new onset or recent increase of >0.5g/24h). 4. Pyuria (> 5 white blood 
cells/high power field, excluding infection) (Table 2). In our studies, LN is defined according 
to SLEDAI except for the criterion pyuria because this often turned out to be due to sample 
contamination.  
 
Histopathology and classification of LN 
It is not possible to accurately determine the severity of renal inflammation based on 
urine sediment findings, amount of proteinuria, glomerular filtration rate or serum parameters 
like creatinine, complement-levels and autoantibody profiles. Renal biopsy has thus become 
the preferred method of classifying renal pathology. Renal biopsy was first introduced in the 
1951 (70) and has become a customary examination in the work up of renal diseases. 
Although this procedure has become safer by ultrasound guidance, taking a renal biopsy 
remains an invasive procedure that leads to life-threatening complications in approximately 
0.1 % of the cases (71). 
The original World Health Organisation (WHO) classification of glomerulonephritis 
in SLE patients from 1974 was revised in 1982 and again in 1995 (72). The latter contained 5 
different classes of LN. This classification  was again modified in 2003 by members of the 
International Society of Nephrology and Renal Pathology Society (ISN/RPS) to provide a 
more concise description of various lesions and classes of LN (73) (Table 3). The features of 
glomerular disease activity (potentially reversible) and sclerosis (irreversible damage) were 
added to these criteria in each class of LN. This is done by a semi-quantitative analysis (on a 
scale from 0 to 3+) of specific histological features of activity or sclerosis. Another class was 
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added to the WHO classification of LN, class VI indicating advanced sclerosis without 
residual activity (Table 3).  
The impact of updating the classification of LN has rendered into a sharper distinction 
between the six different classes (Table 4). All parameters in the recent ISN/RPS 
classification of LN are considered important for prognosis, a potential for targeted therapy, 
and aim to facilitate a higher degree of diagnostic reproducibility of renal biopsy (73). While 
few studies have reported LN prognosis by ISN/RPS classification, the new criteria still lead 
to a considerable discordance between renopathologists in classifying renal biopsies in SLE 
(74). Also, the evaluation of tubulo-interstitial and vascular structures is not well defined and 
has only received a short recommendation, which still leaves room for the use of NIH 
(National Institutes of Health) activity - and chronicity scores of biopsies (73). As indicated 
by the abbreviated ISN/RPS classification of LN (Table 4), class I and II represent milder 
disease and are associated with a good prognosis. In most studies, severe LN that carries the 
highest risk for renal failure is defined as class III or IV, the latter observed in approximately 
40% of biopsies. However progression from class II to class III/IV occurs in about 20-25% of 
patients while conversion from class III to class IV occurs in over two-thirds of patients (75). 
This class switching, in addition to selection bias and a relative new system of classifying LN, 
makes it difficult to get a clear overview of the frequency of the different classes. Some 
approximately values are presented in Table 4. 
 
Pathogenetic mechanisms of LN  
The induction of renal autoimmunity in LN has been a subject of intense investigation, 
and given the limited availability of human material these studies are often based on findings 
in experimental models of lupus prone mice. However, in addition to the difficulties of 
translating mice data to the human model, the various mice models (NZB/W F1, MRL/lpr, 
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BXSB) have their own particularities in terms of progression and type of renal pathology and 
immune abnormalities including autoantibody profile (76). 
The immunological self-intolerance in LN involves a range of different cell types, 
although activated B- and T cells play a major role in this process. B cells express a diverse 
repertoire of immunoglobulins against a wide array of pathogens, and can function as antigen 
presenting cells to T lymphocytes. The antigenic specificity of a B cell is determined through 
the process of gene rearrangement, resulting in antigen-specific cell-surface receptors. These 
receptors together with MHC class II and co-stimulatory molecules like CD80 and CD86 
expressed on B cells makes the antigen-presentation to T cells possible. As illustrated in 
Figure 1, CD4 T-cells bind to the MHC class II/antigen and co-stimulatory molecules with its 
antigen-specific cell-surface receptors and co-stimulatory molecules CD28. However, some of 
these antigen-specific receptors on B cells may develop specificity for self-antigens that for 
unknown causes escapes the strict selection in the thymus that normally prevents self-
intolerance. Upon stimulation by a T cell, which usually occurs in germinal centers in the 
spleen and lymph nodes, the activated B cell differentiates into more specialized cells and is 
clonally expanded to plasma cells that produce autoantibodies. These autoantibodies are 
central in the development of inflammation as they can bind to ubiquitous cells that are 
carrying Fcγ receptors, and trigger the expression of various cytokines (6;72). While the 
initial triggering event for self antigen exposure and the exact proceedings remain unclear, the 
cytokine secretion by B cells (IL-2, IL-6, IL-10, TNF-α as well as the pro-inflammatory 
cytokine IFN-γ) (77) clearly contributes to the development of LN. In the kidneys,  through 
Fcγ receptors situated on the surface of diverse glomerular cell types, autoantibodies binds 
and join together with exposed autoantigens from the circulation or in situ autoantigens and 
form glomerular immune complex depositions which ultimately induce cell and tissue injury 
(78).  
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The immunological self-intolerance in lupus nephritis. B cells act as an ‘self ’-antigen presenting 
cells to T cells. On the cell surface, B cells express immunoglobulins, MHC class II and co-
stimulatory molecules like CD80 and CD86 while CD4 T cells express antigen-specific receptors 
and the co-stimulatory molecule CD28. This B-T cells interaction, which usually occurs in the 
spleen and lymph nodes, makes the activated B cell differentiate into more specialized cells like 
plasma cells that produce large volumes of antibodies.
B cell CD4 T cell










 Even though sera from SLE patients often contain multiple autoantibodies, only few 
have a known nephritogenic potentials,  such as high avidity Ab against anti-dsDNA (40 - 90 
%), anti-Sm (5 - 50 %), anti-C1q (80 - 100 %) and anti-nucleosome (6;79). In the last 
decades, anti-dsDNA Ab are the most extensively studied, based on their serological profile in 
patients with LN and they are enriched in glomerular immune deposits (4;77;80;81). 
In murine models, immune complexes can be demonstrated as electron dense deposits 
in the basement membrane in the renal glomeruli (82). These deposits contain oligo-
nucleosomes (nucleosomes consist of dsDNA wound around a histone protein core) that are 
bound to anti-dsDNA Ab. The oligo-nucleosomes are thought to originate through ineffective 
fragmentation and clearance of apoptotic material (83;84). Although the origin of the 
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apoptotic material in the renal glomeruli is not clear, it may stem from renal mesangial cells 
or infiltrating leukocytes. In this scenario, the presence of anti-dsDNA Ab is secondary to 
abnormal renal apoptosis. 
Another study has shown that Ab which are eluted from the kidney of nephritic mice 
have a higher affinity for DNA compared with serum anti-DNA Ab (85), indicating that these 
autoantibodies obtained their nephritogenic potential through repeated antigen stimulating 
cycles, probably through exposure to apoptotic material (80). This theory of affinity 
maturation of anti-DNA Ab over time  is in agreement with the landmark clinical US military 
study, demonstrating a mean onset of anti-DNA Ab of 2.2 years before SLE diagnosis (86).  
A similar time lag has been registered for antibodies against antiphospholipid (aPL) 
and also these Ab have been shown to be present prior to anti-dsDNA Ab development (87). 
aPL Ab are seen in 30 - 50 % of patients with LN and represent an additional risk factor for 
trombotic events including renal and glomerular capillary thrombosis (88;89). This process 
may be initiated by intraluminar accumulation of fibrin (90). As early as the 1980s, Kant 
showed that the snake poison “ancrod” decreased fibrin deposition and crescent formation, 
and improved renal function in LN through decreasing factor VII and von Willebrand factor 
levels, normalizing platelet hyperaggregation and increasing prostaglandin I2 (91;92). In 
accordance with this, renal impairment in LN is partly due to an exaggerated synthesis of a 
thromboxane antagonist (93;94). Thus, we assume that the autoantibodies in SLE follow a 
predictable course to obtain the nephritogenic potential. The antibodies progressively 
accumulate prior renal damage, subsequently complex immune deposits are formed which 
may provoke renal damage and thrombosis as implied in Figure 2.   
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Pre-clinical SLE Clinical SLE
Genetic susceptibility Autoimmunity Tissue Damage
Triggers
Amplification and determinant spreading
Stages of lupus pathogenesis.
Genetic factors and environmental triggers act on the immune system to initiate autoimmunity. 
Autoantibodies and their autoantigens, cytokines and chemokines amplify immune system 
activation and generate tissue damage. Autoantibody production occurs years prior to the 
development of clinical signs and symptoms of SLE. Organ damage has likely occurred by the 
time lupus is diagnosed.





Immunomodulating treatment in LN 
The goals of therapy in LN are the prevention of renal failure and mortality through 
early induction and long-term maintenance of remission. For this purpose, several regimes 
have been studied and represent the one area in SLE research where randomised clinical trials 
are available to guide management. These studies have in addition been the basis for similar 
approaches to renal involvement in patients with other types of systemic diseases involving 
the kidneys, such as the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis 
(95). 
  The long running series of NIH studies on LN treatment showed monthly intravenous 
(i.v.) cyclophosphamide (CYC) (0.5-1 g/m²) to be more efficacious for maintaining life 
sustaining renal function than oral regimes of azathioprine (96). Thus in almost two decades, 
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monthly i.v. CYC for 3 months followed by quarterly monthly i.v. CYC for 12 to 24 months 
was used as a standard treatment for induction and maintenance of remission in LN. However, 
azathioprine has fewer side effects such as severe infections and amenorrhea compared with 
CYC and was considered as the standard remission maintenance treatment (97).  
Over the last decade several controlled trials have compared various regimens of CYC. 
The Euro-Lupus Nephritis Trial examined the effect of “low-dose” vs. “high-dose” CYC and 
concluded that both are equally efficacious, however severe infections were more common in 
the high dose treated group (98). A similar conclusion was drawn from a Dutch LN study (99) 
that compared high dose CYC with azathioprine and found them equally effective, although 
the flare rates were lower after treatment with CYC. In addition, retrospective study of 
patients with proliferative LN from Northern Norway that compared treatment with 
azathioprine versus pulse CYC showed similar renal survival rates and patient survival rates 
(100). As a result, short time i.v. CYC and corticosteroid pulse therapy are currently the 
commonly accepted standard treatment for induction as high cumulative doses of CYC are  
associated with significant toxicity, particularly infections, malignancy (bladder and ovarian) 
and infertility. According to the Euro-Lupus Nephritis Trial, this induction regimen should be 
followed by azathioprine treatment in the maintenance phase (67). 
Despite improvements in LN treatment, failures to induce remission, subsequent 
relapses and treatment toxicity are remaining clinical challenges hence new alternative 
treatments have been investigated. Mycophenolate mofetil (MMF) is a relative new oral 
immunosuppressive drug used extensively in transplant medicine to avoid CYC toxicity and 
was first given to LN patients’ refractory to CYC (101). Later studies have also confirmed 
that MMF is equally efficient as i.v. CYC as treatment in patients with LN. Treatment with 
MMF may even be more beneficial over i.v. CYC for remission induction in black patients 
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(67;101). Furthermore, MMF is preferred over CYC as induction therapy, since MMF does 
not lead to ovarian toxicity. In maintenance treatment, MMF is equal to azathioprine (67). 
Rituximab is an anti-CD20 monoclonal antibody and was the first biological antibody 
used to specifically target B cells in humans. There were high expectations regarding its use 
in SLE patients, since B cells are highly involved in SLE/LN. The EXPLORER (The 
Exploratory Phase II/III SLE Evaluation of Rituximab) and the LUNAR (LUpus Nephritis 
Assessment with Rituximab) were high-quality randomised controlled trials of Rituximab by 
the treatment of non renal lupus and proliferative lupus nephritis. Both the EXPLORER and 
LUNAR trial were unable to detect a large clinical effect in patients with very active disease. 
There has been much discussion about the disappointing results of these studies, which may 
have been too strict in their outcome measures. A problem with both trials is that patients 
entered with very active disease and therefore they had to be treated with moderate- to 
highdose corticosteroids. Such concomitant therapy makes any benefits from experimental 
treatment difficulty to detect unless the effects are very strong (102). Case series and registry 
data indicate a disease modifying role for Rituximab at least in resistant cases (103). 
  
Supportive treatment in LN  
In all patients with renal disease, it is important that patients maintain normal blood 
pressure to avoid deterioration of renal function and prevent cardiovascular disease (104). As 
proteinuria alone increase the risk of progressing renal disease and may even increase the 
incidence of hyperlipidemia and thrombosis, blood pressure should be less than 130/80 mm 
Hg (105). Since treatment with both antihypertensiva as ACE-I and ARB results in lower 
blood pressure and additionally reduce proteinuria, these drugs should be used, either alone or 
in combination (67). When nephrotic syndrome (proteinuria > 3 g/L, hypoalbuminemia and 
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edema) occurs in patients with LN, treatment with diuretics is recommended as long as edema 
persists (67). 
Regular controls of blood lipids are important because all patients with SLE are at 
increased risk of cardiovascular diseases. Proteinuria as seen in LN, may increase serum lipid 
levels. If dyslipidaemia is observed in SLE patients, dietary changes and weight reduction 
should be considered prior to medical treatment. Statins are the preferred drug (with a target 
LDL cholesterol < 2.6 mmol/l) as they also may have anti-inflammatory effect (106). A 
coagulation screening including protein C, protein S and ATIII levels is indicated in patients 
with significant proteinuria , while in patients with aPL aspirin should be considered, 
especially when vascular disease already is present (105). In addition, hydroxychloroquine 
should be considered as a basic medication in all SLE /LN patients as it helps to avoid flares 
in SLE disease, as well as to reduce the risk of LN relapses (107).  
 
B-cell activating factor (BAFF)  
B cell activating factor (BAFF, TNFSF13 or BLyS) belongs to the tumor necrosis 
factor (TNF) superfamily and is an important stimulatory factor for B cell development, B cell 
homeostasis and immunoglobulin production (108). BAFF is found as a transmembrane 
protein on a range of immune cells. The biologically active 29 kD subunit from BAFF are 
proteolytically cleaved at furin consensus sequences and exists as a soluble protein (Figure 3) 
(109;110). BAFF production can be stimulated by different inflammatory cytokines such as 
IL-2 and INF-γ (111;112). BAFF is the primary determinant of B-cell longevity and numbers 
of mature B-cells because it attenuates B-cells apoptosis by interfering with the NF-κB 
pathway (110;113). Binding of BAFF to the different receptors on mature B cells (BAFF-R, 
TACI and BCMA), induces either Ig class switching, cell proliferation or increased survival 




BAFF exists in membranebound and soluble forms and bind to three distinct receptors: B-cell
maturation antigen (BCMA), transmembrane activator and calcium-modulator and cyclophilin
ligand interactor (TACI) and BAFF receptor (BAFF-R). All receptors are predominantly










BAFF in SLE  
The above mentioned functions of B cells are all relevant in the pathogenesis of 
human SLE, when considering the importance of B cells as antigen presenting cells and 
precursors for autoantibody production.  
In lupus prone mice, serum-BAFF (s-BAFF) levels are increased at disease onset and 
blocking of BAFF-dependent signals with soluble receptor prolongs their survival (114). 
Transgenic mice over expressing BAFF are developing B cell hyperplasia and 
hypergammaglobulinemia. In addition, a striking increase in circulating autoantibodies can be 
measured and an immune complex mediated disease occurs with features of SLE disease 
(115;116).  
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In SLE patients, s-BAFF levels are frequently elevated and associated with the 
presence of anti-dsDNA Ab (117-120). These findings suggest that BAFF is involved in the 
selective loss of immune tolerance in some the B cell types in human SLE, resulting in 
autoantibody production. This hypothesis initiated several clinical trials targeting B cells in 
SLE patients (121). 
Great expectations have been related to treatment with various monoclonal antibodies 
that specifically recognizes and inhibits the biological activity of BAFF. Belimumab, a fully 
human monoclonal antibody, has been assessed in patients with active SLE. The result of a 
phase 3, dose-ranging, randomised placebo-controlled trial of belimumab with standard care 
in patients with SLE is recently published (122). This trial showed efficacy of belimumab in 
controlling SLE in a broad range of patients, and thus, may be the first targeted biological 
treatment that is approved specifically for SLE.  
 
Role of TNFSF13b/BAFF gene in SLE 
The mechanisms that are responsible for the increased s-BAFF levels in SLE are 
currently unclear, however genetic predisposition has been postulated to be one of the 
mechanisms involved (123;124). The B cell hyperactivity in SLE patients could be due to 
specific mutations/polymorphisms in the BAFF gene (TNFSF 13b), localized at chromosome 
13.  Such mutations/polymorphism may influence the expression/stability of the BAFF 
transcript. However, the only available report on the BAFF genotype was performed in a 
Japanese SLE patient cohort. In this study no mutations/polymorphisms were found in the 
coding region of TNFSF-13b. The authors of this study were neither able to find an 
association between disease susceptibility and single nucleotide polymorphisms (SNPs) in the 
5 ' regulatory region of the BAFF gene (13q32-34) (125). However, an association between 
anti-Ro/La positivity and a specific BAFF haplotype (CTAT) has been shown in Caucasian 
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patients with primary Sjögren's Syndrome (pSS) (126). Also, c.-871 T allele in the 5’ 
regulatory region of the BAFF gene has been associated with increased s-BAFF levels in 
patients with pSS and indicating that this SNP may be involved in increased BAFF expression 
(126). 
Increased s-BAFF levels in SLE may be linked to increased BAFF gene expression. 
Several studies have shown that BAFF gene expression can be increased through interferon 
type I inducible cytokines (127;128). In a cross sectional study on Chinese SLE patients, 
BAFF gene expression in peripheral blood mononuclear cells (PBMCs) was shown to be 
correlated with disease activity and anti-dsDNA Ab levels (129). However, in a longitudinal 
North American study, BAFF mRNA was not associated with s-BAFF levels in 60% of the 
investigated patients (118). The discrepancies between these few reports as well as the small 
number of SLE patients studied make it difficult to draw solid conclusions. Consequently 
more studies are required to determine the relative contribution of polymorphisms/mutations 













5. AIMS OF THE STUDY  
Paper I 
The aim in paper I was to validate the ACR97 classification criteria (24) and determine to 
what extent the introduction of aPL antibodies may have influenced the epidemiology, disease 
presentation and management of SLE in Northern Norway. To achieve this, data on incidence, 
prevalence, SMR and survival were obtained in a recent inception cohort and then compared 
with results from a historical inception cohort based on the ACR82 classification criteria 
(23;30). These findings provided insight into the changes over time in the clinical 
epidemiology of SLE in Northern Norway. 
 
Paper II 
The aim of paper II was to elucidate the reasons behind the remarkable reduction of LN 
prevalence in the 97acr cohort observed in paper I. We wanted to investigate if and how the 
inclusion of aPL Ab in the ACR97 criteria had affected the frequency and severity of LN in 
the context of the increased awareness of cardiovascular morbidity. To this purpose, we 
evaluated the clinical presentation, laboratory findings, histological severity and management 
of disease in patients with or without LN in both cohorts. These findings provided insight into 




The aim of paper III was to determine whether increased circulating levels of BAFF in 
patients with SLE can be related to increased gene expression and/or variations in the genetic 
structure of the promoter region of the BAFF encoding gene. Correlations between four SNP 
in the regulatory region of the BAFF gene, BAFF gene expression s-BAFF levels, and 
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different clinical and laboratory findings were investigated. These findings help to improve 





6. SUMMARY OF RESULTS 
 
Paper I: The influence of the 1997 updated classification criteria for Systemic Lupus 
Erythematosus: Epidemiology, disease presentation, and patient management. 
Two inception cohorts of SLE patients in Northern Norway based 97acr (n=58, 
enrolled during 1996 -2006 using ACR97/ACR82) and 82acr (n=81, enrolled during 1978-
1995 using ACR82) were compared to investigate the possible effects of ACR97 criteria. The 
mean annual incidence of SLE was slightly higher for cohort 97acr vs. cohort 82 acr, (3.00 vs. 
2.63 p=0.5). The crude point prevalence of SLE at January 1, 2007, was 64.1/100,000 overall 
(109/100,000 in females). In cohort 97acr, significant fewer patients were presented with 
renal disease (OR 0.28), in contrast to the presence of autoantibodies such as anti-dsDNA 
(OR 2.57) and aPL (OR 27.9). Also, initial treatment with methylprednisolone (OR 9.23), 
azathioprine (OR 6.32), and low-dose aspirin (OR 20.9) was more common in cohort 97acr. 
In addition, five- and ten years survival (95.2 %, 91.9 %) were improved in cohort 97acr 
compared to 82acr. 
This article demonstrates that by use of the ACR97 criteria, the presentation of 
autoantibodies at disease onset increases while SLE patients are more aggressive treated. 
 
 
Paper II: Decreased incidence of lupus nephritis in northern Norway is linked to 
increased use of antihypertensive and anticoagulant therapy. 
Using a similar approach as in paper I, reasons for the decreased frequency of LN 
were sought in two cohorts 97acr (n = 62) and 82acr (n = 87). Between 1978 and 2006, the 
AIR for LN decreased from 0.7 to 0.45/100 000, while the LN prevalence rose from 7 to 
14/100 000. The relative risk reduction in the 97acr for early- and late-onset LN ( > 3 months 
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after SLE diagnosis) was 39 % and 42 %, respectively. During the first 10 years of disease, 
LN development in all patients (n = 39) was significantly associated with SLEDAI ≥ 10 (HR 
6.3), hypertension (HR 3.0) and ESR > 20 (HR 3.0).  
Patients who developed LN in the 97acr cohort (97LN+; n = 11) had similar 
demographics and histological findings by renal biopsy as the 82acr cohort (82LN+; n = 28). 
However in 97LN+, more often low avidity anti-dsDNA Ab and/or aPL Ab were present at 
onset of SLE diagnosis, while proteinuria and diastolic blood pressure were lower than in 
82LN+. Following onset of LN diagnosis, more 97LN+ patients received pulse corticosteroids 
(55 % vs. 7 %), anticoagulants (46 % vs. 4 %) and antihypertensive drugs (46 % vs. 11 %). 
During a 10-year follow-up, three 82LN+ patients (11 %) developed ESRD versus none in 
97LN+.  
These findings indicate that a strategy including early diagnosis based on low avidity 
anti-dsDNA- and aPL Ab testing combined with early initiation of treatment can reduce the 
occurrence and severity of LN. This paper hints at the possibility of LN prevention. 
 
Paper III: Increased levels of BAFF in patients with Systemic Lupus Erythematosus are 
associated with acute phase reactants, independent of BAFF genetics. 
This cross sectional study investigated the role of BAFF in 101 Caucasian SLE 
patients and 111 healthy controls. We found that genetic variation in the promoter region of 
the BAFF encoding gene are not associated with SLE susceptibility, BAFF gene expression in 
PBMCs or increased s-BAFF. Increased BAFF mRNA levels were found in SLE patients (RQ 
1.8 vs.1.1, p<0.001) and BAFF-RQ correlated inversely with CD4+ lymphocytes (β -0.27, 
p<0.012) and IgG levels (β -0.25, p = 0.023). S-BAFF was increased in SLE patients (1.73 vs. 
0.98 ng/μl, p<0.001) and was strongly correlated with acute phase reactants. CRP (β 0.40, 
p<0.001) and inversely with haemoglobin levels (β -0.32, p<0.001) and IgA levels (β -0.33, 
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p=0.001). Also, s-BAFF was increased in SLE patients with anti-dsDNA Ab compared with 
patients without anti-dsDNA Ab (2.2 ng/μl vs. 1.6, p=0.009).  
This paper indicates that increased s-BAFF is the result of local antibody mediated 




 Ethics  
Clinical studies (paper I and II) 
Written informed consent was obtained from all patients in the study. The study was approved 
by the local ethical committee. 
 
Experimental study (paper III) 
Experimental protocols and the establishment of a patient biobank were approved by the local 
ethical committee, the national privacy agency and the Ministry of Health (ref. no 12420). 
 
Study design 
Paper I and II are retrospective longitudinal observational studies while paper III is a case 
control study designed as a cross-sectional study. 
 
Study participation 
Clinical studies (paper I and II) 
The data for the studies are derived from the Tromsø Lupus Cohort, a longitudinal population-
based registry of SLE patients in Northern Norway. The Tromsø Lupus Cohort was 
established in 1997 by J.C. Nossent (30) and in recent years it has been upgraded several 
times. All SLE patients in this register meet the classification criteria for SLE disease, either 
through ACR82 (23) or ACR97 (24) (Table 1). Paper I and II are based on information on 
SLE patients from all rheumatology outpatient clinics throughout Northern Norway including 
the Department of Rheumatology at University Hospital in Northern Norway (UNN). The 
data were recorded during the years 1978-2006 and the SLE patients ( > 15 years) were 
divided in two cohorts based on the year they were diagnosed with SLE disease. The oldest 
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cohort (82acr) included patients with SLE onset during 1978-1995, using the ACR82 
classification criteria, while the youngest cohort (97acr) included patients with SLE onset 
during 1996-2006 using the ACR97 classification criteria. These two inception cohorts were 
compared in both paper I and II.  
 
Experimental study (paper III) 
The patients in paper III are a selection from Tromsø Lupus Cohort. At the same day, they 
were extensively clinical examined and blood samples were drawn for analyses used in this 
study as well as for storage of serum, DNA and RNA. Hundred and one SLE patients (>15 
years) were investigated in the period 2006-2008. The patients were mainly (99 %) of 
Caucasian descent and 87 % were female. The median age was 47 years and median disease 
duration was 10 years. In the SNP analysis, 111 healthy controls were included; 71% were 
female and the median age was 48 years. In the studies of BAFF gene expression and s-BAFF 
levels only 31 healthy controls were included and also these controls had similar gender and 
age as the SLE cohort.  
 
Data collection  
The time of SLE diagnosis was defined as the point of time when the patients 
cumulatively fulfilled at least four ACR criteria, using either ACR82 or ACR97 (Table 1). 
Disease duration was recorded as the time interval from SLE diagnosis until the last follow up 
visit or time of death in paper I and II. 
Data for each hospital consultation for each patient were recorded in a database using 
a predefined data sheet. This included demographics, clinical findings and medication 
together with results of routine haematology surveys, biochemistry analysis and immunologic 
tests. In paper III, patients underwent an extensive clinical examination followed by collection 
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of blood samples for laboratory assays, DNA and mRNA. For every hospital visit the disease 
activity was calculated using SLEDAI (53) and organ damage development was scored by 
SDI (57), preformed by an experienced rheumatologist. All information was obtained directly 
from patients or indirectly from hospital records. When information on clinical items were not 
available or could not be retrieved from other sources, they were scored as not being present. 
Medication was assessed at every consultation; oral prednisolone usage was recorded in 
mg/day, while for other drugs the use of the specific drug for at least three months was 
required for recording in the clinical studies (paper I and II). In paper III, only the presently 
used drugs were included. 
 In paper II, arterial hypertension and results form renal biopsies were central features. 
Our definition on arterial hypertension followed accepted guidelines and consisted of blood 
pressure exceeding 140/90 mmHg (135/90 mmHg for persons < 40 years) or the use of 
antihypertensive drugs for more than 3 months (104). Renal tissue obtained through 
percutaneous biopsies was re-evaluated independently by two pathologists for the following 
features classification of LN as defined by ISN/RPS 2003 classification of LN (73;130), 
Activity and Chronicity indices as defined by the NIH (131) and the presence of 
vasculitis/vascular thrombi. Histological scores in paper II represent the mean score of the 
evaluations done by the two independent pathologists. 
 
Laboratory methods 
Serology, in paper I, II and III 
Routine laboratory investigations reported in all studies were performed in Department 
of Laboratory Medicine and Immunology at UNN.  
ANA-positive sera were routinely tested by enzyme immunoassays (VarELISA 
Phadia, Freiburg) for the presence of IgG subclass antibodies against double stranded DNA 
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(anti-dsDNA), Ro (anti-SSA), La (anti-SSB), Smith (anti-Sm), anti-U1 small nuclear 
ribonucleoparticle (anti-U1-snRNP) and  cardiolipin (aCL-G and aCL-M; normal levels  < 16 
IU/mL). In addition, ANA-positive sera were tested for high avidity anti-dsDNA Ab by 
Crithidia Lucilliae assay (normal < 1:10) until 2001 and thereafter by enzyme linked 
immunosorbent assay (ELiA) (Pharmacia, Germany) (normal levels < 15 IU/ml). Lupus 
anticoagulant (LA) was tested in a three step, phospholipid-dependent coagulation assay 
(132). 
 
Experimental study, paper III  
S-BAFF levels were measured in patients’ serum using a Quantikine Human 
BAFF/BLyS/TNFSF13B Immunoassay (R&D, USA). All measurements were done in 
duplicates and results were averaged.  
In the SNP analysis genomic DNA was extracted from whole blood and purified 
according to the instructions provided (Puregene Genomic DNA purification Kit, Gentra 
systems, Minneapolis, Minnesota, USA). The primers and probes were designed using the 
LightCycler Probe Design Software (Roche Diagnostics, Mannheim, Germany). Primers 
specific sequences are detailed in paper III (Supplemental Table).  
Primers and probes for BAFF gene expression were designed using the BAFF 
encoding gene TNFSF13B (NC_000013.10) and B2M gene encoding β2-microglobulin (β2M) 
(NC_000015.9) as templates. Primers were designed using Enhanced Avian HS RT-PCR 
software (Sigma-Aldrich, Saint Quentin Fallavier, France) and probes were selected using 
Universal ProbeLibrary Human Gene Assay (Roche) (Table 1, Paper III).  
PBMCs were separated by Lymphoprep™ (Axis-Shield, UK) and the cells were stored 
frozen as pellets or in RNA later. Total RNA from frozen mononuclear cells was extracted 
using RNeasy Mini Kit (Qiagen, Hilden, Germany), following manufacturer’s instructions. 
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RNA was DNase I treated, and stored at -80ºC until the samples were thawed and used to 
synthesize cDNA by SuperScript VILO cDNA Synthesis Kit (Invitrogen, CA, USA) 
according to the protocol provided by manufacturer. Real-time PCR analysis was performed 
to determine the levels of BAFF mRNA in PBMCs using an ABI PRISM 7900HT, (version 
2.3, Applied Biosystems, CA, USA). PCR reactions were done in triplicates. The BAFF 
transcript quantification was standardized using β2M as internal control, BAFF-RQ was 
calculated as the ratios of BAFF mRNA to β2M mRNA using the following formula: 2 
exp(Ctβ2M – CtBAFF). Cut-off level of BAFF-RQ was determined by the geometric mean + 
2 SD of healthy controls (n = 31). More detailed description can be found under the section on 
methodology in paper III. 
 
Data analysis and statistics 
Due to relatively small patient numbers in the cohorts and subgroups in addition to the 
fact that most data had a skewed distribution reported numbers are median values (unless 
indicated otherwise) and nonparametric test methods were used in statistical analyses. 
Continuous data were analyzed by Mann-Whitney U test and dichotomous data by Poisson 
distribution contingency tables or Fishers’ exact test in case of low numbers. Correlations 
were analyzed by Spearman rank correlation coefficients. Annual incidence rate (AIR) and 
point-prevalence (PP) are reported per 100,000. Survival rates were estimated by Kaplan-
Meyer method and compared by log-rank tests. Standardized mortality rates (SMR) were 
calculated by randomly assigning each patient 5 controls, born in the same year and month 
and matched for sex and municipality by area code. Risk factors were analysed by Cox 
proportional hazard models, and hazard ratio (HR) were reported with 95% confidence 
intervals (CI).  
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To determine the potential associations between different variables, all associations 
with a p-value < 0.2 in univariate analyses were entered into multiple regression models. If 
appropriate, interdependence was corrected. Statistical analyses were performed with SPSS v 
11.0 or 17.0 and Epi Info version 4.1, while genotype and haplotype analyses were performed 




8. GENERAL DISCUSSION 
 
 The investigation of possible changes in the clinico-epidemiological characteristics of 
SLE in Troms and Finnmark was performed with longitudinal retrospective studies in paper I 
and II. In paper III, we used a cross sectional case control study design to investigate the 
genetic and serologic significance of the cytokine BAFF in SLE. There are particular 
concerns with each of this type of studies that must be taken into account when the results are 
interpreted. 
 
Paper I  
The ACR criteria (22-24) represent the result of extensive statistical modelling to 
reach the lowest amount of heterogeneity in SLE study cohorts. While some of the included 
criteria have changed over the years, the basic principle of minimum four criteria to be 
classified as SLE has not changed. Our data show that the latest change in 1997 lead to a 
small, but not statistically significant increase in the number of new cases per year, as overall 
AIR increased from 2.6 in cohort 82acr to 3.0 in cohort 97acr. This trend, we assume is 
associated with the increased use of assays to detect autoantibodies in cohort 97acr that 
resulted in diagnosis of SLE at an earlier stage of disease development. This is in accordance 
with the theory put forward in Figure 2, where autoantibody production occurs years prior to 
the development of clinical symptoms of SLE and shows that such a using this strategy 
confers clinical benefits. The fact that neither AIR nor diagnostic delay changes were 
significantly different is most likely due to the limited number of patients. 
SLE remains a clinical syndrome with a diverse phenotype that is also variable over 
time in each single patient. ACR criteria are often used as the basis for a clinical diagnosis of 
SLE, even though this practice has several drawbacks. Firstly, the application of ACR criteria 
leads to selection of patients with a classical SLE presentation and excludes patients not 
 42
fulfilling four of the required ACR criteria. In clinical practice, this may lead to a situation 
where patients with less than four classical ACR criteria but several non-classical 
manifestations such as alopecia and Raynaud’s phenomena, are not appropriately diagnosed 
and/or managed e.g. by not receiving beneficial treatment such as antimalarial drugs. The 
importance of considering SLE as a progressive disease is emphasized in paper I and II with 
regard to early diagnosis and treatment. Early diagnosis may lead to increased survival of SLE 
patients partly by reducing LN severity.  Most likely, the narrow ACR97 criteria should be 
reconsidered, as shown by the development of the Boston criteria (134). The Boston criteria 
set reflect the inclusion of patients with objective findings of SLE in a weighted system, 
highest weight corresponding to presence of renal disorder (especially patients with LN, 
WHO class III-VI), discoid rash and cytopenias. Accordingly patients with less than 4 ACR 
criteria can be defined as SLE. The Boston Criteria identifies 7 % patients more compared 
with the current ACR criteria, while these criteria still retain face validity. Thus, a system like 
this could minimize selection bias and increase the generalizability of clinical SLE studies. If 
the currently ACR criteria allow more emphasis on anti-dsDNA- and aPL Ab, renal findings, 
alopecia, Raynaud’s phenomenon and even hypertension, probably more patients would be 
diagnosed earlier in SLE disease development. Such changes in a new criteria-set can be done 
by increasing the number of criteria similar as the ARA from 1971 (Table 1) and/or introduce 
different weighted criteria as the Boston criteria.  
In both papers I and II, patients with less than four ACR criteria have been excluded 
from the studies. In a study from the same region published in 2001, an overview was 
published of SLE patients and patients with diagnosis that might develop SLE (30). This 
study demonstrated that as much as 17 % of the patients, with diagnosis such as lupus-like 
disease (6 %), unclassified and mixed connective tissue disease (4 %), drug induced lupus (2 
%) and discoid lupus (5 %), might in theory develop SLE over time. This finding is in 
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agreement with other studies showing that patients with typical symptoms of SLE without 
fulfilling four of the ACR criteria will develop sufficient classification criteria over time 
(32;135;136). These considerations have an implication on the current study presented in 
paper I and II, since the selection criteria for entry into Tromsø Lupus Cohort was according 
to the ACR criteria. 
It is also important to realize that several clinical manifestations were excluded during 
the development of the SLE criteria set from 1971 to 1997 (Table 1). Currently, a patient may 
manifest a multisystem disease consistent with SLE without fulfilling the ACR criteria or 
even opposite; a patient can fulfil four ACR criteria while the clinical diagnosis of SLE is 
questionable. The criteria such as photosensitivity and malar rash are highly interrelated and 
there is also a strong correlation between positive test of anti-dsDNA Ab and ANA (137). In 
clinical practice, the impact of including patients with interrelated criteria is not of great 
importance, but a few questionable SLE patients are probably included in most SLE cohort 
studies, although this does not need to have a major impact on the results. In paper I, we 
concluded that increased serological surveillance with ELISA-based assays of anti-dsDNA 
and aPL Ab have contributed to include a number of patients with milder lupus. These 
findings were based on the use ACR97 criteria, where autoantibodies are more emphasized 
compared with the ACR82 criteria.  
In the future, the increased use of 97ACR criteria as well as the increased serological 
surveillance, will probably contribute to earlier diagnosis of more SLE patients. 
 In epidemiological studies, the selection of patients is often a challenge, and 
inconsistencies can result in large discrepancies that may invalidate results obtained. 
Therefore, in paper I and II, the methods for selecting SLE patients were especially important 
to minimize sources of error in epidemiological calculations. In paper I, our goal was to find 
all SLE patients in Troms and Finnmark (which has an approximately population on 225 000 
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inhabitants) and include them in Tromsø Lupus Cohort. To enrol patients with SLE, we got 
access to databases from all departments in hospitals and clinics in this area. The journal of 
the patients with diagnosis codes that could be related to SLE were reviewed with respect to 
the classification criteria for SLE was fulfilled. Despite our inclusion criteria, we had no 
guarantee that SLE patients would not be missed, for example because of limited recognition 
by general practitioners, patients having quiescent SLE for prolonged periods of time disease 
or because some patients had recently moved to Troms and Finnmark. By being aware of 
these sources of errors, we used a capture-recapture analysis of incidence studies. 
Accordingly, we estimated that the proportion of potentially missed patients is up to 2.4 % 
(138).  
 
The gold standard for evidence in clinical research comes from prospective, controlled 
and randomized trials. Such studies allow the quantification of absolute and relative risk 
associated with a specific condition and/or treatment. Given the low frequency of new onset 
SLE with only 2-3 cases per 100,000 adults in our study area, an inclusion period of ten years 
would give a modestly sized cohort of 50-60 incident cases. Furthermore, financial efforts for 
regional collaboration, that would have increased our cohort size, have so far failed. The 
current observational study of all SLE patients in Troms and Finnmark within a certain 
timeframe is therefore a practical compromise that balances the aims of our study with the 
available resources. As several similar incidence studies exists and average AIR of 2.8 in 
paper I is in accordance with the reported Scandinavian incidence rates (1.5 – 4.8) (27;29-32), 
we assume that our inclusion methods are satisfactory and appropriate for further study. 
 
A major challenge in retrospective observational studies as in paper I and II, where 
potential factors and outcome of interest are recorded, is to draw conclusions that are 
 45
sufficiently free from bias. The recorded factors are sometimes not directly responsible for the 
observed differences in the results, while other unregistered factors actually are related to the 
observed differences. Furthermore, recorded or unrecorded factors may be correlated with 
each other and may lead to incorrect conclusions. In addition, as the number of recorded 
factors increases, the likelihood that at least one of the recorded factors will be highly 
correlated with the outcome increases simply by chance. Recognizing the limitations of this 
type of study, guidelines are developed recently by The Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE). This initiative includes 22 
recommendations on what should be included in an accurate and complete report of an 
observational study (139). While our studies were initiated before these guidelines were 
available, there is considerable although not complete agreement between the 
recommendations and the presentation of our results.   
 
The laboratory data reported are based on routinely performed analyses at UNN). The 
quality of these data is ensured by standardisation of methods including regular quality 
control checks, as well as participation in a national accreditation process. The immunology 
laboratory has a similar quality control system for the detection of autoantibodies by ELISA 
techniques and complement levels measured by standard nephelometry, where the quality of 
the methods used are ensured by participation in an international accreditation process (UK 
NEOAS). The laboratory data reported in all the three papers included are considered reliable 
and representative for clinical practice. 
 
The database of registered SLE patients was established in 1997. The updated database 
used for paper I and II contained a total of 2671 registered hospital visits with a maximum of 
261 variables that were recorded per visit. This large amount of data entailed specific 
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problems in terms of data management and subsequent newly introduced analyses. Almost all 
observational research has to deal with missing data. The most common procedure is to omit 
those cases with missing data and to run analyses on remaining records. However, this 
method may lead to a loss in statistical power, making it a less attractive option for variables 
with more than 5 % missing values. Another method use imputation (substitution of values 
for a missing data point) for which several procedures are available. Imputation was applied 
in paper I and II, where missing data for potential predictors of survival and LN were 
substituted with group mean values in order to retain sufficient power for multivariate 
analyses.  
Once the data set was considered as complete as possible after applying the above 
mentioned corrections, subsequent data analyses was facilitated by the use of statistical 
computer software (SPSS). The use of nonparametric methods in the evaluation of group 
differences resulted in stringent conditions of the reported statistical analyses. This was done 
to avoid type I errors (false positive results), although this increased the risk of type II errors 
(false negative results). Type II errors may exist in all papers in this study, where subgroups 
with low numbers resulted in limited statistical power and accordingly increases the risk of 
not detecting a real existing difference. 
 
 
Paper II  
The methods applied in paper II were to a large extent similar as paper I and the 
arguments in the discussion above are also valid for paper II. However, the specificities of 
renal disease and its implications merit further discussion. 
Main findings in paper II were that early detection of autoantibodies with sensitive 
assays in combination with early treatment, including administering antihypertensives and 
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anticoagulants, can contribute to reduce the prevalence and severity of LN, with subsequent 
improved renal survival. Therefore, it seems important to diagnose and treat SLE patients as 
early as possible, and preferably before manifestation of several renal symptoms occurs, 
because once these are observed, the risk for organ damage increases sharply. This treatment 
strategy is in accordance to the current paradigm in the management of inflammatory joint 
diseases, where early diagnosis and treatment is instituted to avoid the development of erosive 
bone lesions. In our study, no significant differences were seen between the cohorts regarding 
the various ISN/RPS classes or NIH Activity or Chronicity Indices scores. The histological 
findings at LN diagnosis in patients with SLE showed a majority of proliferative lesions 
(ISN/RPS class III and IV), and the overall percent for these lesions in our cohorts is in 
agreement with a review report of Tumlin (Table 4) (140). Currently, no patients with LN in 
the 97acr cohort have developed ESRD or advanced renal damage (as ISN/RPS class V or VI) 
by renal biopsy findings. This is in contrast to the above mentioned report showing that 10 -
20% of renal biopsy from patients with LN was evaluated as ISN/RPS class V. All together, 
this may indicate that renal damage in the last cohort included (97acr) in our study has 
become less severe.  
 
Concerning the initial development of autoreactive Ab in SLE/LN patients, this can be 
due to molecular mimicry of viral or bacterial antigens with self-determinants that may 
succeed in epitope spreading (141). Epitope (the binding-site of Ab with antigen) spreading 
involves the recognition of new epitopes within the same antigen. The term also covers 
epitopes residing in proteins that are associated in the same macromolecular complex like the 
nucleosome, that in fact is the main autoantigen circulation in patients with SLE (142). This 
initial binding, as seen in Figure 1, implies further the progression of an autoimmune response 
to a chronic state involving increased targeting of autoantigens by T cells and Ab. Once 
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immune tolerance to one component is abrogated, B- and T-cell responses can diversify to 
other components of the macromolecule with the recognition of other epitopes in the intact 
particle. Over time, most likely epitope spreading results in amplification of autoimmunity 
that includes production of autoantibodies as shown in Figure 2. 
The above mentioned theory is strengthened based on results of LN in mouse 
experiments. In mice, IgG autoantibodies against dsDNA or nucleosomes are detected in 
serum before clinical findings like proteinuria occur, indicating the fact that nephritogenic 
autoantibodies play a central role in LN (82). Two main hypotheses exist explaining how 
antibodies are involved in the development of LN. 1) Antibodies cross-react with non-
nucleosomal glomerular antigens, or 2) they recognise exposed chromatin fragments 
associated with glomerular basement membranes (82;143;144). Regardless to which theory 
account, this autoimmune development of LN over time is in line with our results in paper II, 
where the incidence of LN decreased simultaneously with increased detection of low avidity 
autoantibodies, which suggesting that SLE patients were identified earlier in the disease 
course. 
Both general practitioners and rheumatologist should however emphasize the detection 
of autoantibodies to a greater extent because this is an early warning that these patients 
probably will develop SLE. Studies have shown that detection of anti-DNA-, anti-nucleosome 
and aPL Ab occurs several years before onset of SLE disease (86;87).  In a recent study from 
Northern Sweden, it was shown that the interval between a positive test for anti-dsDNA Ab 
and diagnosis of SLE was as long as 6.6 years (145). These results are in agreement with 
paper I, where the SLE patients in the cohort 97acr had more detected autoantibodies as 
criterion of SLE and less clinical manifestations including renal disease.  
Even when patients do not meet the four ACR criteria, but rather have diffuse 
symptoms that may be associated with SLE including these autoantibodies; they should be 
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regarded as having an as yet unclassified autoimmune disease that may require intervention. 
Such patients will therefore need to be evaluated by a consultant in Rheumatology and 
follow-up needs to be scheduled.  Urinalysis is easy to perform and provides much 
information about renal involvement in SLE patients by detection of proteinuria and/or 
erythrocytes. This basic investigation should be done regularly in general practice, and if 
abnormalities are detected, also urinary microscopy should be performed before the 
examination at the rheumatologic outpatient clinic. Hypertension is associated with renal 
impairment, hypercholesterolaemia and increased risk of coronary heart disease in patients 
with SLE. Therefore, blood pressure should be monitored closely and if systolic blood 
pressure > 130mm Hg and diastolic > 80mm Hg are measured, patients should be treated with 
ACE-I and/or ARB which also reduce proteinuria (105). Anticoagulation should be 
considered for patients with aPL and/or increased risk of cardiovascular disease. 
Implementing the outlined strategy for earlier diagnosis, referral and intervention in 
clinical practice will be a major challenge, as doctors need to rethink their tendency to 
diagnose SLE patients mainly based on clinical symptoms according to the ACR criteria. 
Given it relative ease and health benefits for each patient, this message should be clearly 
brought forward to the general practitioners. 
 
Paper III 
 We investigated the importance of BAFF in patients with SLE and applied a cross 
sectional, case control study design. We are aware of the limitations of this study as Stohl and 
his colleagues who conducted a longitudinal observational study of SLE patients and showed 
that levels of s-BAFF and BAFF mRNA in PBMCs varies over time. In addition to a marked 
heterogeneity of the persistent s-BAFF and BAFF mRNA levels, intermittent elevated levels 
were registered (118). Since BAFF is a signal molecule and the levels present may fluctuate 
in blood in single individuals, the study design that we chose has an intrinsic weakness. 
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Ideally, a longitudinal study to investigate the temporal relationship between s-BAFF and 
BAFF gene expression should have been preformed to complement our data.  
Assays for measuring s-BAFF levels were performed at the Rheumatology Research 
Laboratory at the University of Tromsø. A longstanding experience with ELISA based 
determination of antibodies, along with the regularly carried out quality control check, 
ensured the robustness of our analysis. S-BAFF analyses were performed with commercially 
available kits based on ELISA techniques that have undergone pre-marketing quality controls. 
Since BAFF is a short-lived cytokine involved in paracrine cell communication, it was 
important to minimize the time from blood samples were taken to the serum was frozen. 
Accordingly, blood samples were processed within two hours after the samples were 
retrieved, even though during this time various molecules in serum might be degraded. Also, 
the freezing of serum samples prior to analysis could have caused a bias, because cytokines 
are sensitive to freeze-thawing procedures. However, all measurements were performed on 
sera that had been frozen only once, in accordance with other studies on serum BAFF (118). 
Currently, 366 SNPs are recognized in the BAFF gene (www.ncbi.nlm.nih.gov/snp). 
Four of the examined SNPs in the5’ promoter region of the BAFF gene were selected based 
on findings from other articles (125;126;146). Whereas c.-514 (A>G) was chosen because it 
might be associated to the NF-κB pathway and thereby inhibiting apoptosis (113). The 
haplotypes, associated with the SNPs located within the promoter were in strong linkage 
disequilibrium (p<0.00001). Our study was a genetic pilot study to see if any obvious 
associations between the examined SNPs and SLE susceptibility existed. Given the small 
differences we noted, the cohort size need to increase by at least a factor ten to reach 
sufficient statistical power. While the protocol for this BAFF study was planned years before 
the results of genome wide studies were available, the lack of association in our study is 
nonetheless consistent with current findings in GWAS (147).  
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The assays used for the SNPs analysis were designed and performed in Laboratory 
Medicine Department, whereas BAFF gene expression was investigated in Medical Genetic 
Department, UNN. These departments have long experience with similar assays, including 
quality control tests. Regarding to BAFF gene expression assays, cDNA was synthesized 
from total RNA at the Rheumatology Research Laboratory at the University of Tromsø. Since 
no correlation with BAFF gene expression and s-BAFF levels were observed, we speculate in 
paper III that a negative feedback mechanism may exist. In agreement with a previous 
Chinese study (129), we found increased BAFF mRNA in SLE patients compared to controls. 
In contrast to our findings, Ju and colleagues found increased BAFF mRNA correlated with 
anti-dsDNA Ab levels. However, correlation between BAFF mRNA and s-BAFF levels was 
not examined in this Chinese study, where only 37 SLE patients were included. 
We did find a strong inverse correlation of BAFF gene expression with numbers of 
CD4+ T-cells, in disagreement with Morimoto and colleagues who suggested that 
autoantibody production is driven by BAFF produced by T cells and may accordingly play a 
pathological role in SLE (148). Their results are based on the expression of BAFF mRNA in 
isolated cultured T cells of SLE patients. Since neither s-BAFF levels nor their relation with 
BAFF gene expression were reported in that study, it is not possible to determine in which 
extent BAFF production by CD4+ cells is affecting the s-BAFF levels. The discrepancy 
between the BAFF gene expression and s-BAFF levels, have also been reported elsewhere 
(118) and suggest that the origin of s-BAFF is more complex. Therefore, our data support a 
prior suggested hypothesis that a negative regulatory feedback mechanism may exist between 
s-BAFF levels and BAFF mRNA expression in PBMCs (146).  
In paper III, increased s-BAFF was associated with the acute phase reactants CRP and 
hemoglobin, but not with ESR, autoantibodies and hypocomplementemia which usually 
reflect SLE disease activity. CRP levels on the other hand do not reflect disease activity in 
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SLE very well, except for that very high levels of CRP are seen in SLE patients with 
polyarthritis, serositis or a bacterial infection. Therefore, the correlation between s-BAFF and 
CRP in our study may reflect cytokine signalling to hepatocytes, related to production of 
CRP. Increased production of CRP may be related to the presence of antibodies against CRP 
or the tissue binding of CRP on immune complexes that reduces serum CRP availability 
(149). In response to infection or injury, local inflammatory cells (neutrophils, granulocytes 
and macrophages) secrete a number of proinflammatory cytokines into serum, most notable of 
which are the interleukins IL-1, IL-6 and IL-8, and TNF-α, which further stimulates 
hepatocytes to produce CRP.  
Anemia of chronic disease is a common manifestation in rheumatic diseases, and is 
related the above mentioned cytokines included CRP (150). Since s-BAFF was associated to 
both anemia and CRP it would be interesting to conduct a new study to see if there are any 
correlation between s-BAFF and any of the proinflammatory cytokines in SLE patients. S-
BAFF was also associated with the presence of anti-dsDNA Ab, although it did not correlate 
with the levels of autoantibodies. Secretory IgA in the mucosa is important to protect 
individuals against microorganisms. In paper III, a significant inverse correlation between s-
BAFF and IgA was seen, which can either be caused by impaired production of IgA or 









9. MAIN CONCLUSIONS 
1. The use of the 1997 update of the ACR classification criteria of SLE, did not lead to 
significant changes in SLE incidence or demographics when compared to the 1982 
criteria (Paper I).  
2. The mean AIR of LN in Northern Norway decreased from 0.7 during 1978-1995 to 
0.45 in during 1996-2006, with a relative risk reduction of developing LN of about 
40% (Paper I and II).  
3. Increased use of sensitive assays for anti-dsDNA- and aPL Ab during 1996-2006 at 
the onset of both SLE and LN seems to have contributed to earlier identification of 
patients at risk for severe disease (Paper I and II). 
4. This early detection by sensitive assays for anti-dsDNA- and aPL Ab together with an 
early and more aggressive therapeutic approach, seems to have contributed to a milder 
disease course and subsequent improvements in survival (Paper I). 
5. Early detection of low avidity assays for anti-dsDNA and aPL Ab, probably in 
combination with early treatment that includes immunosuppressive and vasoprotective 
drugs have contribute to reduced incidence of LN and improved renal survival       
(Paper II).   
6. Polymorphisms in the BAFF promoter do not increase the susceptibility for SLE in a 
Nordic population (Paper III). 
7. In SLE patients, s-BAFF is at increased levels independent of BAFF promoter 
polymorphisms or BAFF mRNA expression in PBMC (Paper III).  
8. Increased levels of s-BAFF in SLE patients are not correlated with overall measures of 
disease activity, but with positive test of anti-dsDNA Ab (Paper III).  
9. Increased levels of s-BAFF in SLE patients are associated with acute phase proteins    
(Paper III). 
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10. S-BAFF production most likely occurs at specific sites where anti-dsDNA Ab is 
involved in the inflammatory process (Paper III). 
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Table 1  Changes in the classification criteria of SLE. 1971 preliminary criteria for SLE, 
ACR82: American College of Rheumatology (ACR) - revised classification criteria for SLE, 
published in 1982 and ACR97: updated classification criteria for SLE, published in 1997. For 









Tot. sensitivity  
96 % 





Tot. sensitivity  
78 % 












1. Malar rash Malar rash Malar rash 57 98 
2. Discoid lupus Discoid lupus Discoid lupus 18 99 
3. Photosensitivity Photosensitivity Photosensitivity 43 96 
4. Oral ulcers Oral ulcers Oral ulcers 27 96 
5. Arthritis Arthritis Arthritis 86 37 
6. Serositis Serositis Serositis 56 86 
7.a) Proteinuria >0.5 g/d Proteinuria >0.5 
g/d Proteinuria >3.5 g/d 51 94 
7.b) Urinary cellular casts Urinary cellular 
casts Urinary cellular casts 36 97 
8. Neurologic disorders Neurologic 
disorders Neurologic disorders 20 98 
Haemolytic anemia 
or leucopenia* or 
thrombocytopenia 9. 
Haemolytic anemia 




or leucopenia* or 
thrombocytopenia 
or lymphopenia* - 
59 89 
10.a) Pos. aCL/ LA Ab - - 50 85 
10.b) Pos. anti-dsDNA Ab Pos. anti-dsDNA 
Ab - 67 92 
10.c) Pos. anti-Sm Ab Pos. anti-Sm Ab - 30 98 
10.d) 
Chronic false-




test for syphilis 
Chronic false-
positive serologic test 
for syphilis 
15 99 
11. Pos. ANA  Pos. ANA  - 99 49 
 - Positive LE cells Positive LE cells 73 96 
 - - 
Raynaud’s 
phenomenon 29 81 
 - - Alopecia 56 88 
* Requires two or more occasions 
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Table 2  SLEDAI, data collection sheet. 
   SLEDAI 
(Enter weight in SLEDAI. Score column if descriptor is present at the time of the visit or in the preceding 10 days) 
Study No.: Patient name:  Visit date:  
    day month ye
ar 
    
Weight SCORE Descriptor Definition 
    
8  Seizure Recent onset, exclude metabolic, infectious, or drug causes. 
8  Psychosis Altered ability to function in normal activity due to severe disturbance 
in the perception of reality. Include hallucinations, incoherence, 
marked illogical thinking, bizarre, disorganized, or catatonic 
behaviour. Exclude uraemia and drug causes. 
8  Organic brain 
syndrome 
Altered mental function with impaired orientation, memory, or other 
intellectual function, with rapid onset and fluctuating clinical 
features, inability to sustain attention to environment, plus at least 2 
of the following: perceptual disturbance, incoherent speech, 
insomnia or daytime drowsiness, or increase or decrease 
psychomotor activity.  
Exclude metabolic, infectious or drug causes. 
8  Visual disturbance  Retinal changes of SLE. Include cytoid bodies, retinal hemorrhages, 
serous exudates or hemorrhages in the choroid, or optic neuritis.  
Exclude hypertension, infection, or drug causes 
8  Cranial nerve disorder New onset of sensory or motor neuropathy involving cranial nerves. 
8  Lupus headache Severe, persistent headache; may be migrainous, but must be 
nonresponsive to narcotic analgesia. 
8  CVA New onset of cerebrovascular accident(s). Exclude arteriosclerosis. 
8  Vasculitis Ulceration, gangrene, tender finger nodules, periungual infarction, 
splinter hemorrhages, or biopsy or angiogram proof of vasculitis. 
4  Arthritis > 2 joints with pain and signs of inflammation (i.e., tenderness, swelling 
or effusion). 
4  Myositis Proximal muscle aching/weakness, associated with elevated creatine 
phosphokinase/aldolase or electromyogram changes or a biopsy 
showing myositis. 
4  Urinary casts Heme-granular or red blood cell casts. 
4  Hematuria > 5 red blood cells/high power field. Exclude stone, infection or other 
cause. 
4  Proteinuria >0.5 gram/24 hours 
4  Pyuria >5 with blood cells/high power field. Exclude infection. 
2  Rash Inflammatory type rash. 
2  Alopecia Abnormal, patchy or diffuse loss of hair. 
2  Mucosal ulcers Oral or nasal ulcerations. 
2  Pleurisy Pleuritic chest pain with pleural rub or effusion, or pleural thickening. 
2  Pericarditis Pericardial pain with at least 1 of the following: rub, effusion, or 
electrocardiogram or echocardiogram confirmation. 
2  Low complement Decrease in CH50, C3 or C4 below the lower limit of normal for testing 
laboratory. 
2  Increased DNA 
binding 
Increased DNA binding by Farr assay above normal range for testing  
laboratory. 
1  Fever >38° C. Exclude infectious cause.  
1  Thrombocytopenia <100,000 platelets / x109 /L, exclude drug causes. 
1  Leukopenia <3,000 white blood cells / x109 /L, exclude drug causes. 
    
TOTAL    




Table 3. The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited 
International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification of lupus 
nephritis.  
 
Class I Minimal mesangial lupus nephritis 
     Normal glomeruli by light microscopy, but mesangial immune deposits by 
immunofluorescence 
Class II Mesangial proliferative lupus nephritis 
     Purely mesangial hypercellularity of any degree or mesangial matrix expansion by light 
microscopy, with mesangial immune deposits  
     May be a few isolated subepithelial or subendothelial deposits visible by 
immunofluorescence or electron microscopy, but not by light microscopy  
Class III Focal lupus nephritisa 
     Active or inactive focal, segmental or global endo- or extracapillary glomerulonephritis 
involving <50% of all glomeruli, typically with focal subendothelial immune deposits, with 
or without mesangial alterations  
    Class III (A) Active lesions: focal proliferative lupus nephritis 
    Class III (A/C) Active and chronic lesions: focal proliferative and sclerosing lupus nephritis 
    Class III (C) Chronic inactive lesions with glomerular scars: focal sclerosing lupus nephritis 
Class IV Diffuse lupus nephritisb 
    Active or inactive diffuse, segmental or global endo- or extracapillary glomerulonephritis 
involving ≥50% of all glomeruli, typically with diffuse subendothelial immune deposits, with 
or without mesangial alterations. This class is divided into diffuse segmental (IV-S) lupus 
nephritis when ≥50% of the involved glomeruli have segmental lesions, and diffuse global 
(IV-G) lupus nephritis when ≥50% of the involved glomeruli have global lesions. Segmental 
is defined as a glomerular lesion that involves less than half of the glomerular tuft. This class 
includes cases with diffuse wire loop deposits but with little or no glomerular proliferation  
    Class IV-S (A) Active lesions: diffuse segmental proliferative lupus nephritis 
    Class IV-G (A) Active lesions: diffuse global proliferative lupus nephritis 
    Class IV-S 
(A/C) 
Active and chronic lesions: diffuse segmental proliferative and sclerosing lupus nephritis 
 Active and chronic lesions: diffuse global proliferative and sclerosing lupus nephritis 
    Class IV-S (C) Chronic inactive lesions with scars: diffuse segmental sclerosing lupus nephritis 
    Class IV-G (C) Chronic inactive lesions with scars: diffuse global sclerosing lupus nephritis 
Class V Membranous lupus nephritis 
     Global or segmental subepithelial immune deposits or their morphologic sequelae by light 
microscopy and by immunofluorescence or electron microscopy, with or without mesangial 
alterations  
     Class V lupus nephritis may occur in combination with class III or IV in which case both 
will be diagnosed 
     Class V lupus nephritis show advanced sclerosis 
Class VI Advanced sclerosis lupus nephritis 
     ≥90% of glomeruli globally sclerosed without residual activity  
a Indicate the proportion of glomeruli with active and with sclerotic lesions.  
b Indicate the proportion of glomeruli with fibrinoid necrosis and/or cellular crescents.  
Indicate and grade (mild, moderate, severe) tubular atrophy, interstitial inflammation and fibrosis, severity of 
arteriosclerosis or other vascular lesions.   
         (Weening et al 2004) 
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Table 4. Abbreviated International Society of Nephrology/Renal Pathology Society 
Classification of Lupus Nephritis (2003)*  








 No specific therapy** 
Class III Focal lupus nephritis† 25 – 30 % 
Mild: As for class II or steroids   
Moderate: Steroides ± MMF/AZA         
Severe: See treatment for class IV 
Class IV 
Diffuse segmental (IV-
S) or global (IV-G) 
lupus nephritis‡ 
40 % 
Induction (6 months): CYC or MMF 









 No specific therapy 
Additional comments 
* Indicate and grade (mild, moderate, and severe) tubular atrophy, interstitial inflammation and 
fibrosis, severity of arteriosclerosis, or other vascular lesions (73). 
† Indicate the proportion of glomeruli with active and with sclerotic lesions. 
‡ Indicate the proportion of glomeruli with fibrinoid necrosis and cellular crescents. 
§ Class V may occur in combination with class III or IV, in which case both will be diagnosed. 
**Angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers are 
recommended as adjunct therapy for proteinuria in all classes (151). 
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